Video

The Number of Women Having Strokes is Rising

Preventative Mastectomy

Cases of Gestational Diabetes Are On the Rise

Nintendo Wii Could Be Therapy for Stroke Victims

Single Men Have An Increased Risk for Stroke

Fatty Foods Could Lead to Stroke in Older Women

Woman Gives Birth After Ovary Transplant

Cancer Foundation Raises Money for Neuroblastoma

Too Much Weight Gain During Pregnancy Could Lead to Diabetes

New CT Scanners Use 90% Less Radiation

Music Education Can Shape a Child's Sensory System

Food Warning Labels Could Help Prevent Choking Hazards

Acupuncture May Relieve Depression in Pregnant Women

The Economy Could Lower Life Expectancy

HPV Can Be Studied On Dolphins

Arzerra Approved for Chronic Lymphocytic Leukemia

Posted on 10/27/2009, 10:40
By -- Scott Roberts

Affects some 16,000 people annually

TUESDAY, Oct. 27 (HealthDay News) -- Arzerra (ofatumumab) has been approved by the U.S. Food and Drug Administration to treat chronic lymphocytic leukemia (CLL), a cancer of the blood and bone marrow.

The drug, produced by London-based GlaxoSmithKline, is approved when other types of chemotherapy no longer control the disease, the FDA said in a news release.

CLL, a slowly progressing form of leukemia, mostly affects people aged 50 and older. Some 16,000 people annually are diagnosed with the disease, and about 4,400 die, the agency said.

Arzerra binds to white blood cells known as B cells, making it easier for the body's immune system to fight cancerous B cells. The drug was approved under an accelerated process granted to drugs that satisfy unmet medical needs, the FDA said. Ongoing studies will establish whether combining Arzerra with standard forms of chemotherapy delays progression of CLL.

Common side effects recorded during clinical testing of Arzerra included an increased risk of progressive multifocal leukoencephalopathy (PML), an often-fatal brain infection. Also, people with a history of hepatitis should be carefully monitored while taking the drug.

Other side effects may include a decrease in blood cell counts, pneumonia, fever, cough, diarrhea, fatigue and shortness of breath, the FDA said.

More information

The FDA has more about this drug's approval history.

More news in Leukemia...

BigHealthTree.com Disclaimer

Bighealthtree.com Does Not Provide Medical Advice. This site, including the above information, is for informational purposes only and is not a substitute for professional medical or health advice. Always seek the advice of your physician or a qualified health or medical professional before starting any new treatment, changing existing treatment, or altering your current exercise and/or diet program. If you think you are having a medical emergency, call 911 (or the emergency services in your area) or your doctor immediately.

Rating: 2.9 / 5 (74 votes)